Blood test-guided targeted therapy for advanced melanoma
Part of Cancer, Skin clinical trials.
This study tests if giving you targeted therapy pills (encorafenib and binimetinib) only when a blood test shows your cancer is active — instead of continuously — can help keep the melanoma under control with fewer side effects. It is designed for people with advanced melanoma that has a BRAF mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cutaneous melanoma (melanoma that starts in the skin).
- You are 18 years or older.
- Your melanoma is either stage III that cannot be removed with surgery, or stage IV (it has spread).
- Your melanoma must have a BRAF mutation (specifically V600E, V600K, V600R, or V600D) — this can be checked in a lab.
- You have not had prior BRAF/MEK inhibitor treatment for stage IV melanoma (if you had it for earlier stage, that may be okay).
- You do not have melanoma spread to the brain or the lining around the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding metformin to vemurafenib can shrink advanced melanoma in people with a specific gene change (BRAF V600E). It’s an early-phase trial, so the main goal is to see if the combination is safe and whether it may work better than expected.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
This early-phase study looks at whether people with melanoma can get the “right” follow-up (extra) treatment based on how well their cancer responds after starting targeted drugs before surgery. The goal is to improve outcomes while better matching treatment to each person’s tumor response.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This trial checks how much of two drugs, encorafenib and binimetinib, remain in your blood while treating advanced melanoma that cannot be removed by surgery. The goal is to learn if drug levels affect how well the treatment works.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.